retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial 🚨 Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent and type diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide

Technically yes, but you will see very limited results

No, there is currently no NICE, MHRA, or NHS guidance recommending allulose supplementation for patients receiving GLP-1 therapy

Using them too early may cause: Severe redness Stinging or burning sensation Slow healing Inflammation What you need to do is to soothe your skin and strengthen its barrier

Broad E, Bolger C, Galloway S

GLP-1s are generally well tolerated, with most gastrointestinal side effects subsiding over time

in Cell Metabolism note that SIRT1 activation improves mitochondrial efficiency and promotes a shift toward lipid utilization for energy, which can be especially beneficial in endurance and fat-loss settings (Price et al., Cell Metabolism )